Resonant Capital Advisors LLC Has $2.28 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)

Resonant Capital Advisors LLC boosted its position in Becton, Dickinson and Company (NYSE:BDX) by 0.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,470 shares of the medical instruments supplier’s stock after buying an additional 63 shares during the period. Resonant Capital Advisors LLC’s holdings in Becton, Dickinson and Company were worth $2,283,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Ameriprise Financial Inc. increased its position in shares of Becton, Dickinson and Company by 6.4% during the second quarter. Ameriprise Financial Inc. now owns 5,055,354 shares of the medical instruments supplier’s stock worth $1,181,483,000 after acquiring an additional 302,893 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Becton, Dickinson and Company by 1.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 4,905,114 shares of the medical instruments supplier’s stock worth $1,146,374,000 after acquiring an additional 87,230 shares in the last quarter. Bank of New York Mellon Corp grew its position in Becton, Dickinson and Company by 8.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock worth $1,031,167,000 after purchasing an additional 346,720 shares in the last quarter. Clearbridge Investments LLC grew its position in Becton, Dickinson and Company by 3.1% in the 2nd quarter. Clearbridge Investments LLC now owns 2,984,524 shares of the medical instruments supplier’s stock worth $697,513,000 after purchasing an additional 89,157 shares in the last quarter. Finally, First Eagle Investment Management LLC grew its position in Becton, Dickinson and Company by 32.5% in the 2nd quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock worth $655,149,000 after purchasing an additional 688,296 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Evercore ISI upped their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Raymond James reduced their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Stifel Nicolaus boosted their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Finally, Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their target price for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $282.63.

Becton, Dickinson and Company Price Performance

BDX stock opened at $243.75 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $262.23. The firm’s fifty day moving average is $237.01 and its 200 day moving average is $235.24. The firm has a market cap of $70.45 billion, a P/E ratio of 53.69, a P/E/G ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. The business had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company’s revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.96 EPS. Research analysts predict that Becton, Dickinson and Company will post 13.11 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, September 30th. Shareholders of record on Monday, September 9th were issued a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 1.56%. The ex-dividend date was Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.